Discover
IMVT
Immunovant, Inc.
38.14
2 x 27.47
2 x 48.87
bid
ask
-
0.39
1.01%
2 @ 04:00 PM
38.23 +0.09 (0.24%)
| Ytd | 50.04% | |
| 1y | 136.16% |
37.74
day range
38.87
14.32
52 week range
39.28
| Open | 38.39 | Prev Close | 38.53 | Low | 37.74 | High | 38.87 | Mkt Cap | 7.83B |
| Vol | 828.85K | Avg Vol | 1.95M | EPS | -2.77 | P/E | N/A | Forward P/E | -15.81 |
| Beta | 0.79 | Short Ratio | 7.73 | Inst. Own | 54.74% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 31.78 | 200-d Avg | 25.60 | 1yr Est | 45.76 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-06-04 | 2026-03 | 0 | N/A | N/A | N/A |
| 2026-02-06 | 2025-12 | 0 | N/A | 0.11 | 15.28% |
| 2025-11-10 | 2025-09 | 0 | N/A | -0.01 | -1.39% |
| 2025-11-10 | 2025-09 | 0 | N/A | N/A | N/A |
| 2025-08-11 | 2025-06 | 0 | N/A | N/A | N/A |
| 2025-08-11 | 2025-06 | 0 | N/A | 0.09 | 13.04% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-06-30 | Citigroup | Upgrade | Buy | Buy |
| 2026-05-26 | Guggenheim | Upgrade | Buy | Buy |
| 2026-05-22 | Truist Securities | Upgrade | Hold | Hold |
| 2026-05-21 | B of A Securities | Upgrade | Buy | Buy |
| 2026-05-21 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-04-15 | Goldman Sachs | Upgrade | Neutral | Neutral |
Profile
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-04-15 | BARNETT EVA RENEE | Chief Financial Officer | 396.77K | Sale |
| 2024-08-20 | BUTCHKO JULIA G | Officer | 440.96K | Sale |
| 2026-06-25 | GIRÃO TIAGO M | Chief Financial Officer | 247.60K | Sale |
| 2026-06-25 | GLORIA MELANIE | Chief Operating Officer | 224.39K | Sale |
| 2024-11-19 | LEVINE MARK S | Officer | 319.23K | Sale |
| 2025-02-18 | MACIAS WILLIAM L | Officer | 357.35K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | FMR, LLC | 16.95M | 646.39M | 8.25% |
| 2026-03-30 | Deep Track Capital, Lp | 11.53M | 439.64M | 5.61% |
| 2026-03-30 | Blackrock Inc. | 6.57M | 250.75M | 3.20% |
| 2026-03-30 | Baker Bros. Advisors, LP | 5.46M | 208.16M | 2.66% |
| 2026-03-30 | State Street Corporation | 4.54M | 173.08M | 2.21% |
| 2026-03-30 | TCG Crossover Management, LLC | 4.46M | 170.03M | 2.17% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-05-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 5.10M | 194.46M | 2.48% |
| 2026-05-30 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.84M | 108.35M | 1.38% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.60M | 99.06M | 1.27% |
| 2026-04-29 | iShares Trust-iShares Russell 2000 ETF | 1.91M | 72.97M | 0.93% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.88M | 71.53M | 0.91% |
| 2026-03-30 | T. Rowe Price Small-Cap Stock Fund, Inc. | 1.50M | 57.10M | 0.73% |